Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a span of less than 15 months, Ranbaxy - now part of Japanese pharma Daiichi Sankyo - will see a second changing of the guard, as chief executive Atul Sobti steps down and hands over the reigns to Arun Sawhney, presently serving as president of Ranbaxy's global pharmaceutical business. Sawhney's promotion to managing director is effective Aug. 20

You may also be interested in...



In A Sudden Move, Ranbaxy CFO Omesh Sethi Quits; Analysts Shocked

MUMBAI - In a surprise move, Ranbaxy CFO and President Omesh Sethi tendered his resignation after serving the company for more than two decades in various critical positions

In A Sudden Move, Ranbaxy CFO Omesh Sethi Quits; Analysts Shocked

MUMBAI - In a surprise move, Ranbaxy CFO and President Omesh Sethi tendered his resignation after serving the company for more than two decades in various critical positions

Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?

MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites

Related Content

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel